ASTELLAS-2138-CL-0101
Phase I
OPEN TO ACCRUAL
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
HCRN-GI18-333-SEQUEL
Phase II
OPEN TO ACCRUAL
Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) with Anti-Angiogenesis and Chemotherapy in Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
HOFFMANN-BO41932-TAPISTRY
Phase II
OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
MAYO-18-1612-BIOREPOSITORY
Phase N/A
OPEN TO ACCRUAL
Exploration of tumor biology in patients with metastatic esophageal and gastric cancer (biorepository protocol for prospective tissue collection)
MERCK-MK1084-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRAS G12C Mutant Advanced Solid Tumors
NRG-GY022
Phase I
OPEN TO ACCRUAL
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
XILIO-XTX301-01-02-001
Phase I
OPEN TO ACCRUAL
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors